These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28802404)

  • 1. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
    Mukherjee R; Chandra Pal A; Banerjee M
    Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycobacterium tuberculosis High-Throughput Screening.
    White EL; Tower NA; Rasmussen L
    Methods Mol Biol; 2016; 1439():181-95. PubMed ID: 27316996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.
    Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM
    Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of novel drug targets in Mycobacterium tuberculosis.
    Singh V; Mizrahi V
    Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioluminescent Reporters for Rapid Mechanism of Action Assessment in Tuberculosis Drug Discovery.
    Naran K; Moosa A; Barry CE; Boshoff HI; Mizrahi V; Warner DF
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6748-6757. PubMed ID: 27572410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman RC
    Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Parish T
    Expert Opin Drug Discov; 2020 Mar; 15(3):349-358. PubMed ID: 31899974
    [No Abstract]   [Full Text] [Related]  

  • 10. The relevance of persisters in tuberculosis drug discovery.
    Mandal S; Njikan S; Kumar A; Early JV; Parish T
    Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem.
    Goldman RC
    Infect Disord Drug Targets; 2020; 20(3):352-366. PubMed ID: 30520384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current challenges in drug discovery for tuberculosis.
    Kumar A; Chettiar S; Parish T
    Expert Opin Drug Discov; 2017 Jan; 12(1):1-4. PubMed ID: 27797593
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel and revisited approaches in antituberculosis drug discovery.
    Herrmann J; Rybniker J; Müller R
    Curr Opin Biotechnol; 2017 Dec; 48():94-101. PubMed ID: 28427007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-pathogen systems for early drug discovery against tuberculosis.
    Trofimov V; Costa-Gouveia J; Hoffmann E; Brodin P
    Curr Opin Microbiol; 2017 Oct; 39():143-151. PubMed ID: 29179041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico analyses for the discovery of tuberculosis drug targets.
    Chung BK; Dick T; Lee DY
    J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
    Manning AJ; Ovechkina Y; McGillivray A; Flint L; Roberts DM; Parish T
    Methods; 2017 Aug; 127():3-11. PubMed ID: 28366666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.